Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from AstraZeneca

AstraZeneca CEO Pascal Soriot on why he’s building in the U.S.: ‘Europe is losing ground’

Also: All the news and watercooler chat from Fortune.

Fortune

AstraZeneca unveils plans for £37bn investment in US amid tariff threats

US President Donald Trump has threatened to impose tariffs of up to 20% on drug imports to boost manufacturing in America and drive down costs.

Evening Standard

AstraZeneca pledges $50bn US investment ahead of drugs tariffs

Donald Trump is expected to announce tariffs of up to 200% on drugs makers in August

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

AstraZeneca to invest $50bn in US by 2030 amid Trump tariff threats

UK company to fund new drug manufacturing facility in Virginia and expand R&D facilities around US

The Guardian - UK

FTSE 100 Live 22 July: Sizewell deal lifts Centrica shares, Compass higher after upgrade

Dealmaking Centrica and Compass were the pick of London’s blue chips today as the FTSE 100 index held its position near to last night’s record close.

Evening Standard

Rachel Reeves vows to stick to fiscal rules and declines to rule out wealth tax – as it happened

Rolling coverage of the latest economic and financial news, as chancellor Rachel Reeves testifies to House of Lords economic affairs committee

The Guardian - UK

AstraZeneca's Multi-Billion Dollar Cancer Drug Tagrisso Improves Overall Survival In Patients With Advanced Lung Cancer

On Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial of Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

AstraZeneca's Experimental Therapy Stumbles In Late-Stage Study For Rare Protein Deposit Condition

On Wednesday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase 3 program.

Benzinga

AstraZeneca's Drug Shows Promise For Resistant Hypertension In Phase 3 Trial

AstraZeneca Plc (NASDAQ:AZN) on Monday released topline data from the BaxHTN Phase 3 trial of baxdrostat in patients with uncontrolled or treatment-resistant hypertension.

Benzinga

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.

Benzinga

Business news live: Price of silver shoots to 14-year high and FTSE 100 falls before weekend

Stock markets updates and business news from Friday

The Independent UK

Cathie Wood Vs. Jim Cramer: TV Host Says Top Ark AI Pick 'Losing Money Hand Over Fist'

When it comes to artificial intelligence stocks, there are multiple that are found in the various portfolios of Ark Funds, led by Cathie Wood.

Benzinga

AstraZeneca’s stock market exit would be devastating blow, warns ex-chancellor

The UK is ‘a hostile environment’ for innovative, high-tech growth companies, the Government has been told.

Evening Standard

Stocks fade as tariff deadline looms large

US President Donald Trump said he plans to start sending letters informing trading partners of their tariff rates.

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

If AstraZeneca goes to the US, it will be a major blow for London and Labour

Move would deprive LSE of its biggest star and could topple a key pillar of the government’s industrial strategy

The Independent UK

What AstraZeneca could cost London stock market if it moves to US

IN FULL

The Independent UK

Fears over £160bn blow to London’s stock market as AstraZeneca considers listing move to US

CEO Pascal Soriot has not hidden his annoyance at taxes and regulations the pharmaceutical firm have to navigate

The Independent UK

Business news live: Gilt yields spike on Reeves exit speculation and CEO of AstraZeneca discusses leaving London

Stock markets updates and business news from Wednesday

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

AstraZeneca boss ‘wants to shift stock market listing to US’

Report claims CEO Pascal Soriot talked in private about moving UK’s most valuable listed company and considered shifting its domicile

MarketBeat

IonQ’s $1B Acquisition and Drug Discovery Leap With NVIDIA

IonQ just hit investors with two pieces of big news. One shows proof of the company's tech being useful near-term. The other looks to aid its long-term goals.

The Independent UK

‘Transformational’ new breast cancer drug could halt the growth of tumours

A trial funded by AstraZeneca found the drug is effective in stopping cancer cells from using hormones to grow

Barchart

Short Sellers Are Taking Aim at Buy-Rated Tempus AI. Should You Buy TEM Stock Here?

Tempus AI stock fell over 19% after Spruce Point Capital released a short report. Can TEM stock recover?

Euronews

How the love story between von der Leyen and Pfizer turned sour

From making her Europe’s vaccine saviour to becoming a skeleton in her closet: All the ebbs and flows in the love story between Ursula von der Leyen and big pharma Pfizer.

The Guardian - UK

Drug price cuts: what is Trump planning and what will it mean for big pharma?

President has directed Robert Kennedy to send price targets to industry, with slimming drugs thought to be included

MarketBeat

Tempus AI Stock: Time to Double Down or Cut and Run?

Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point to significant upside potential.

1 … 3 4 5 6

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.